CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
IPO Year: 2014
Exchange: NASDAQ
Website: caredx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2026 | $26.00 | Buy → Hold | Craig Hallum |
| 8/26/2025 | Mkt Perform | William Blair | |
| 1/15/2025 | $28.00 → $24.00 | Underweight → Equal Weight | Wells Fargo |
| 8/28/2024 | $28.00 | Underweight | Wells Fargo |
| 8/19/2024 | $40.00 | Neutral → Buy | BTIG Research |
| 5/13/2024 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2024 | $15.00 | Hold → Buy | Craig Hallum |
| 11/9/2023 | $10.00 | Equal-Weight → Overweight | Stephens |
| 8/15/2023 | $12.00 | Mkt Perform → Outperform | Raymond James |
| 5/11/2023 | Buy → Neutral | BTIG Research |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
Fastest customizable press release news feed in the world
CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided. About CareDx CareDx is a leading pr
Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per year in years two
NavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202607015393
Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630207907/en/ Under the te
AlloSure® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data support the role of AlloSure® Kidney as a noninvasive tool for longitudinal risk stratification and clinical decision-making CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Ne
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026, at 5:30pm ET. Goldman Sachs 47th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, FL. Fireside chat on Monday, June 8, 2026, at 1:20pm ET. Live and archived webcasts of the presentations will
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. There is no monetary payment associated with the dismissal. The dismissal order follows the request, by the qui tam plaintiff, for dismissal of the case and the Department of Justice's (DOJ) concurrence in that request. The matter w
CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggregate of 63,856 shares of common stock. The RSU awards were made pursuant to the Company's 2019 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 2
Transaction extends CareDx's Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx's FY2026 Adjusted EBITDA guidance CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial
First Quarter Revenue Growth of 39% Driven by Strong Performance Across Testing Services and Patient and Digital Solutions Raises 2026 Revenue Guidance to $447 Million to $465 Million and Raises 2026 AEBITDA Guidance to $43 Million to $57 Million CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing se
8-K - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
DEFA14A - CareDx, Inc. (0001217234) (Filer)
S-3ASR - CareDx, Inc. (0001217234) (Filer)
10-Q - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
DEFA14A - CareDx, Inc. (0001217234) (Filer)
DEF 14A - CareDx, Inc. (0001217234) (Filer)
8-K/A - CareDx, Inc. (0001217234) (Filer)
144 - CareDx, Inc. (0001217234) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $26.00
William Blair initiated coverage of CareDx with a rating of Mkt Perform
Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously
Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00
BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00
Raymond James downgraded CareDx from Outperform to Mkt Perform
Craig Hallum upgraded CareDx from Hold to Buy and set a new price target of $15.00
Stephens upgraded CareDx from Equal-Weight to Overweight and set a new price target of $10.00
Raymond James upgraded CareDx from Mkt Perform to Outperform and set a new price target of $12.00
BTIG Research downgraded CareDx from Buy to Neutral
Live Leadership Updates
Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac
Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation
CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors. Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system for providing highly specialized and innovative care, including solid organ and bone marrow transplantation. Suresh has more than 20 years of executive leadership experience in healthcare administration and information technology, with a proven track record of driving operational
CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep f
CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac
CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx's Board of Directors, effective March 11, 2024. "We're pleased to welcome Bryan to our Board," said Michael Goldberg, CareDx Board Chairperson. "His financial expertise, operating background and deep understanding of revenue cycle management in molecular diagnostics will allow him to make meaningful contributions to our Board." Riggsbee previously served as Chief Financial Officer at Myr
Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson. CareDx will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, Chief Financial Officer Abh
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc. "Grace is a seasoned leader who has founded and managed multiple biotechnology and healthcare businesses," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "As we continue t
Live finance-specific insights
CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided. About CareDx CareDx is a leading pr
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone,
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference ca
Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 4-7, 2026, in Salt Lake City, U
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-274-8461 for domestic callers or 1-203-518-9814 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, plea
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to
Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, pl
This live feed shows all institutional transactions in real time.
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G - CareDx, Inc. (0001217234) (Subject)